ARK Animal Health, Inc is a wholly owned subsidiary of Sorrento focused on applying human therapeutics to treat naturally occurring diseases in companion animals. Therapeutics for pets help us validate future break-through for humans, and in return pets get access to therapies that would otherwise never make it to animal health.
The first example of this approach is the development of resiniferatoxin (RTX). The lead application for RTX in animals will be for the treatment of pain associated with osteosarcoma in companion dogs. In studies of dogs with advanced bone cancer, treatment with RTX led to sustained reduction in levels of pain throughout a 14-week observation period. Investigators noted that pain control remained evident throughout the dogs’ remaining life, which was up to nine months in one case. Ark Animal Health has filed the Effectiveness and Target Animal Safety technical sections of the New Animal Drug Application (NADA) for the control of pain associated with bone cancer in dogs. Ark was granted a Minor Use/Minor Species (MUMS) Drug Designation for ARK-001, a proprietary formulation containing the active ingredient resiniferatoxin, in June 2015. Under the MUMS designation, Ark will be seeking conditional approval of RTX and plans to complete the balance of the NADA application in 2018. Additional development programs will be focused on the treatment of osteoarthritis in dogs, idiopathic cystitis in cats, as well as ocular pain and caudal heel pain in horses.